DEA faces criticism for blocking cannabis research, accused of putting red tape over public health needs.

The DEA is facing criticism for its handling of cannabis research applications, accused of systemic corruption and regulatory negligence. Despite its mission to ensure controlled substances are available for medical needs, the agency has blocked clinical trials by companies like MMJ BioPharma, leaving patients with conditions like Huntington's disease and Multiple Sclerosis without potential treatments. Internal statements suggest the DEA prioritizes bureaucratic red tape over scientific progress and public health.